Updated:
Jubilant Pharma Limited
Jubilant Pharma Limited is a Singapore-based multi-family office run by the Bhartia family, investing in pharmaceuticals, biotech, and healthcare.
Jubilant Pharma Limited
Jubilant Pharma Limited was founded in 1992 by the Bhartia family, with roots in the Indian pharmaceutical sector. The firm's wealth originates from Jubilant Life Sciences, a contract research and manufacturing services (CRAMS) giant, and its subsequent spin-offs. The firm invests across three main verticals: pharmaceuticals (generics, specialty drugs), biotech (research and development), and healthcare services (hospital networks, diagnostics). Specific portfolio companies include Jubilant Biosys, a drug discovery arm, and Jubilant Therapeutics, focused on oncology and CNS disorders. Geographic focus is Asia, with exposure through subsidiaries in North America and Europe (public record, 2023). With a headquarters in Singapore, the firm employs a lean team of professionals who manage direct investments, partnerships, and acquisitions. In May 2024, Jubilant Pharma announced a strategic collaboration with a global biotech firm to accelerate pipeline development (per the firm, May 2024). The firm maintains philanthropic structures via the Jubilant Bhartia Foundation, separately governed. A structural differentiator is the firm's ability to leverage its operating company's manufacturing and R&D expertise for deal sourcing and due diligence. This integrated approach allows it to identify opportunities in regulated markets where vertical integration is a competitive edge.
General information
Firm type
Multi Family Office
Year founded
1992
AUM
Undisclosed
Location
Region
Asia
Country
Singapore
City
Singapore
Corporate office
Singapore, Singapore
Principals
Hari Bhartia
Co-Chairman
Shyam Bhartia
Co-Chairman
Sector focus
Frequently asked questions
Who runs investment decisions at Jubilant Pharma Limited?
Hari Bhartia and Shyam Bhartia serve as co-chairmen and lead investment decisions, drawing on decades of experience in the pharmaceutical industry (public record).
How does Jubilant Pharma source proprietary deal flow?
The firm leverages its operating company, Jubilant Life Sciences, to source deal flow through industry relationships, regulatory networks, and captive R&D platforms.
Is Jubilant Pharma structured as a single family office or does it operate more like a venture firm?
It functions as a multi-family office, managing capital for the Bhartia family while also facilitating co-investments with select family-controlled enterprises.
Does Jubilant Pharma participate in fund commitments or only direct deals?
The firm primarily executes direct investments and strategic acquisitions, but it also engages in partnership structures with other family offices and industrial partners.
What investment stages does Jubilant Pharma typically target?
Jubilant Pharma focuses on growth-stage and mature companies, with an emphasis on those that can benefit from its operational and regulatory expertise.
Which sectors does Jubilant Pharma explicitly avoid?
The firm does not invest in pure consumer goods, real estate, or financial services, preferring industries where its healthcare and biotech expertise provides an edge.
Where does the underlying wealth come from?
The wealth originates from the Bhartia family's founding and scaling of Jubilant Life Sciences, a publicly listed contract research and manufacturing company.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: